Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Oliver Rosen
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Metastatic Colorectal Cancer First-Line Treatment With Bevacizumab: The Impact of K-Ras Mutation
OncoTargets and Therapy
Oncology
Pharmacology
Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
Frontiers in Oncology
Cancer Research
Oncology
Cediranib With mFOLFOX6 vs Bevacizumab With mFOLFOX6 in Previously Treated Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Critical Appraisal of Bevacizumab in the Treatment of Metastatic Colorectal Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis
Oncologist
Cancer Research
Medicine
Oncology
Effect of Application and Intensity of Bevacizumab-Based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-Analysis
Clinical Colorectal Cancer
Oncology
Gastroenterology
A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Effect and Safety of Bevacizumab-Containing Chemotherapy Treatment in Chinese Patients With Metastatic Colorectal Cancer
OncoTargets and Therapy
Oncology
Pharmacology
